Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA

Cancer Biomarkers

Volumn 14, Issue 5, 2014, Pages 295-302

  Ghanjati, Foued ^a   Beermann, Agnes ^a   Hermanns, Thomas ^b   Poyet, Cedric ^b   Araúzo Bravo, Marcos J ^c,e   Seifert, Hans Helge ^d   Schmidtpeter, Martin ^b   Goering, Wolfgang ^a   Sorg, Rüdiger ^a   Wernet, Peter ^a   Santourlidis, Simeon ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^d Nestle Product Technology Centre Singen   (Germany)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

bladder cancer; Cell free DNA; diagnosis; DNA methylation; urine

Indexed keywords

CELL FREE DNA; DNA; UNCLASSIFIED DRUG; URINARY CELLULAR DNA;

ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; BLADDER; BLADDER TUMOR; CASE CONTROL STUDY; CELL FREE SYSTEM; GENETIC EPIGENESIS; GENETICS; PHYSIOLOGY;

CASE-CONTROL STUDIES; CELL-FREE SYSTEM; DNA; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84938685598     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140407     Document Type: Article

References (35)

1. A. Bird, DNA methylation patterns and epigenetic memory, Genes Dev 16 (2002), 6-21.
2. W.A. Schulz, C. Steinhoff, A.F. Florl, Methylation of endogenous human retroelements in health and disease, Curr Top Mi-crobiol Immunol 310 (2006), 211-50.
3. P.A. Jones, S.B. Baylin, The epigenomics of cancer, Cell 128 (2007), 683-692.
4. W.G. Nelson, A.M. De Marco, S. Yegnasubramanian, Epi-genetic alterations in human prostate cancers, Endocrinology 150 (2009), 3991-4002.
5. P.A. Jones, S.B. Baylin, The fundamental role of epigenetic events in cancer, Nat Rev Genet 3 (2002), 415-428.
6. M.E. Hegi, L. Liu, J.G. Herman, R. Stupp, W. Wick, M. Weller, M.P. Mehta, M.R. Gilbert, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methy-lation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol 26 (2008), 4189-4199.
7. R. Grützmann, B. Molnar, C. Pilarsky, J. K. Habermann, P.M. Schlag, H.D. Saeger, S. Miehlke, T. Stolz, F. Model, U.J. Rob-lick, H.P. Bruch, R. Koch, V. Liebenberg, T. Devos, X. Song, R.H. Day, A.Z. Sledziewski, C. Lofton-Day, Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay, PLoS One 3 (2008), e3759.
8. P. Mandel, P. Metais, Les acides nucleiques du plasma sanguin chez l'homme, C R Seances Soc Biol Fil 142 (1948), 241-3.
9. K. Jung, M. Fleischhacker, A. Rabien, Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature, Clin Chim Acta 411 (2010), 1611-24.
10. M. Stroun, P. Anker, P. Maurice, J. Lyautey, C. Lederrey, M. Beljanski, Neoplastic characteristics of the DNA found in the plasma of cancer patients, Oncology 46 (1989), 318-22.
11. H. Schwarzenbach, C. Alix-Panabieres, I. Muller, et al., Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer, Clin Cancer Res 15 (2000), 1032-8.
12. I. Muller, K. Urban, K. Pantel, H. Schwarzenbach, Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia, Ann NY Acad Sci 1075 (2006), 222-9.
13. H. Schwarzenbach, F.K. Chun, I. Lange, et al., Detection of tumorspecific DNA in blood and bone marrow plasma from patients with prostate cancer, Int J Cancer 120 (2007), 1465-71.
14. H. Schwarzenbach, F.K. Chun, I. Muller, et al., Microsatellite analysis of allelic imbalance in tumor and blood from patients with prostate cancer, BJU Int 102 (2008), 253-8.
15. E. Sunami, M. Shinozaki, C.S. Higano, et al., Multimarker circulating DNA assay for assessing blood of prostate cancer patients, Clin Chem 55 (2009), 559-67.
16. P.J. Bastian, G.S. Palapattu, S. Yegnasubramanian, et al., Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy, Clin Cancer Res 13 (2007), 5361-7.
17. E. Papadopoulou, E. Davilas, V. Sotiriou, et al., Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer, Oncol Res 14 (2004), 439-45.
18. A. Altimari, A.D. Grigioni, E. Benedettini, et al., Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer, Am J Clin Pathol 129 (2008), 756-62.
19. I. Muller, K. Urban, K. Pantel, H. Schwarzenbach, Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia, Ann NY Acad Sci 1075 (2006), 222-9.
20. C. Goessl, H. Krause, M. Muller, et al., Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids, Cancer Res 60 (2000), 5941-5.
21. J. Ellinger, K. Haan, L.C. Heukamp, et al., CpG island hyper-methylation in cell-free serum DNA identifies patients with localized prostate cancer, Prostate 68 (2008), 42-9.
22. C. Jeronimo, H. Usadel, R. Henrique, et al., Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer, Urology 60 (2002), 1131-5.
23. J. Reibenwein, D. Pils, P. Horak, et al., Promoter hypermethy-lation of GSTP1, AR, and 14-3-3ó in serum of prostate cancer patients and its clinical relevance, Prostate 67 (2007), 427-32.
24. O.E. Bryzgunova, E.S. Morozkin, S.V. Yarmoschuk, et al., Methylationspecific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients, Ann NY Acad Sci 1137 (2008), 222-5.
25. C.K. Chuang, D.C. Chu, R.D. Tzou, et al., Hypermethy-lation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma, Cancer Detect Prev 31 (2007), 59-63.
26. P.J. Bastian, G.S. Palapattu, S. Yegnasubramanian, et al., CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer, J Urol 179 (2008), 529-34.
27. J. Ellinger, S.C. Müller, T.C. Stadler, A. Jung, A. von Ruecker, P.J. Bastian, The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer, Urol Oncol 29 (2011), 124-9.
28. C. Alix-Panabières, H. Schwarzenbach, K. Pantel, Circulating tumor cells and circulating tumor DNA, Annu Rev Med 63 (2012), 199-215.
29. A. Beermann, F. Ghanjati, T. Hermanns, C. Poyet, J. Pereira, J. Fischer, P. Wernet, S. Santourlidis, Methods for Separate Isolation of Cell-Free DNA and Cellular DNA from Urine-Application of Methylation-Specific PCR on both DNA Fractions, The Open Biomarkers Journal 4 (2011), 15-17.
30. S. Santourlidis, P. Wernet, F. Ghanjati, N. Graffmann, J. Springer, C. Kriegs, X. Zhao, J. Brands, M.J. Araúzo-Bravo, R. Neves, G. Koegler, M. Uhrberg, Unrestricted somatic stem cells (USSC) from human umbilical cord blood display uncommitted epigenetic signatures of the major stem cell pluripotency genes, Stem Cell Res, 6 (2011), 60-9.
31. A. Neuhausen, A.R. Florl, M.O. Grimm, W.A. Schulz, DNA methylation alterations in urothelial carcinoma, Cancer Biol Ther 5 (2006), 993-1001.
32. A.R. Florl, R. Löwer, B.J. Schmitz-Dräger, W.A. Schulz, DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas, Br J Cancer 80 (1999), 1312-21.
33. H.H. Jr. Kazazian, J.L. Goodier, LINE Drive: Retrotransposi-tion and Genome Instability, Cell 110 (2002), 277-80.
34. J. Richter, U. Wagner, P. Schraml, R. Maurer, G. Alund, H. Knönagel, H. Moch, M.J. Mihatsch, T.C. Gasser, G. Sauter, Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer, Cancer Res 59 (1999), 5687-91.
35. H.H. Seifert, V. Schmiemann, M. Mueller, et al., In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer, Exp Mol Pathol 82 (2007), 292-7.